Dr Reddys Laboratories Ltd 6-K, filed Nov 1, 2021
Dr Reddys Laboratories Ltd (RDY)
About this 6-K
Dr Reddys Laboratories Ltd filed this 6-K on November 1, 2021.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
October, 2021
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY’S LABORATORIES LIMITED (Registrant) | |||
| Date: October 29, 2021 | By: | /s/ Sandeep Poddar | |
| Name: | Sandeep Poddar | ||
| Title: | Company Secretary | ||
Exhibit 99.1
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
October 29, 2021
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | “Exchange Plaza” |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai – 400 001 | Mumbai – 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Press Release
Please find enclosed a Press Release on “Dr. Reddy's Laboratories announces the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U.S. Market”
This is for your information.
With regards,
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
Encl: As above
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
NSE IFSC Ltd.
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, | AMIT AGARWAL | USHA IYER |
| Hyderabad - 500034. Telangana, India. | amita@drreddys.com | ushaiyer@drreddys.com |
Dr. Reddy's
Laboratories announces the launch of
Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial
in the U.S. Market
| Hyderabad, India, October 29, 2021 | For Immediate Release |
Hyderabad, India and Princeton, NJ, USA. October 29, 2021 - Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz® (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration (USFDA).
The Akovaz® brand and generic market had U.S. sales of approximately $67.5 million MAT for the most recent twelve months ending in August 2021 according to IQVIA Health*.
Dr. Reddy’s Ephedrine Sulfate Injection USP, 50 mg/mL is a clear, colorless, sterile solution for intravenous injection and supplied as a 1 mL fill in a 2 mL clear glass single-dose vial with purple flip-off cap. Each mL contains 50 mg of ephedrine sulfate USP, equivalent to 38 mg ephedrine base.
Please click here for full prescribing information: https://www.drreddys.com/pi/Ephedrine-Sulfate-Inj-Leaflet-150085475.pdf
| Akovaz® is a trademark of EXELA STERILE MEDICINES LLC |  |
| *IQVIA Retail and Non-Retail MAT August 2021 |
RDY-1021-376
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues. and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.
Exhibit 99.2
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
October 29, 2021
To,
The Secretary
BSE Limited
National Stock Exchange of India Ltd.
New York Stock Exchange Inc.
NSE IFSC Limited
Dear Sir/ Madam,
Sub: Intimation under Regulation 30 of the
SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015
With reference to the above, this is to inform you that Mr. Sandeep Poddar, Company Secretary and Compliance Officer of the Company, has tendered his resignation from the services of the Company to pursue career opportunities outside of the Company. The Board has taken note of his resignation at its meeting today. Mr. Poddar will continue to act as the Company Secretary and Compliance Officer of the Company until the close of business hours on Thursday, November 18, 2021.
The Company places on record its appreciation for the contributions made by Mr. Sandeep Poddar during his tenure as the Company Secretary and Compliance Officer of the Company and wishes him the very best in his future endeavours.
The Company has initiated the succession process for the said position and necessary intimation in this regard will be sent in due course of time.
The Board has designated Mr. Vivek Mittal, Global General Counsel of the Company as Interim Compliance Officer under Regulation 6(1) the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015 with effect from Friday, November 19, 2021.
This is for your information and records.
Yours faithfully,
For Dr. Reddy's Laboratories Limited
| /s/ G V Prasad | |
| G V Prasad | |
| Co-chairman and Managing Director |
Exhibit 99.3
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
October 29, 2021
To,
The Secretary
BSE Limited
National Stock Exchange of India Ltd.
New York Stock Exchange Inc.
NSE IFSC Limited
Dear Sir/ Madam,
Sub: Intimation
This is to inform you that the audit of our formulations manufacturing facilities (FTO 7 & FTO 9) at Duvvada, Visakhapatnam, by the US FDA, has been completed today. We have been issued a Form 483 with 8 (eight) observations, which we will address within the stipulated timeline.
This is for your information.
Yours faithfully,
For Dr. Reddy's Laboratories Limited
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
Exhibit 99.4
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
October 28, 2021
The Secretary
National Stock Exchange of India Ltd.
BSE Ltd.
New York Stock Exchange Inc.
NSE IFSC Ltd.
Dear Sir/Madam,
Sub: Intimation for allotment of equity shares on exercise of ESOP and grant of stock options.
This is to inform you that the Nomination, Governance and Compensation Committee of the Board of Directors of the Company has approved the allotment of 1,114 equity shares of Rs.5/- each of the Company, fully paid up, on October 28, 2021 to employees pursuant to exercise of their Stock Options as per the following details:
| a) | 1,014 equity shares of Rs. 5/- each pursuant to Dr. Reddy's Employees Stock Option Scheme, 2002. |
| b) | 100 equity shares of Rs. 5/- each underlying 100 ADRs pursuant to Dr. Reddy's Employees ADR Stock Option Scheme, 2007. |
Please find enclosed the details as required under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
This is to further inform you that the Nomination, Governance & Compensation Committee of the Board of Directors of the Company has also granted the following stock options to employees of the Company:
| Sr. No. |
Type of Option | Number of options granted |
Value |
Exercise Price |
ESOP Scheme |
| 1 | Indian stock options | 156# | Fair market value | 4,663 | Dr. Reddy's Employees Stock Option Scheme, 2018 |
| 2 | 2,524# | Par value | 5 | Dr. Reddy's Employees Stock Option Scheme, 2002 | |
| 3 | 30,208* |
(#) 25% vesting each year, starting after one year from the grant date
(*) 50% vesting at the end of second year and 50% vesting at the end of third year from the grant date
This is for your information and records.
With regards,
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
Encl: as above
Details under Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
| 1 |
Company name and address of Registered Office: Dr. Reddy's Laboratories Limited 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500034 |
| 2 |
Name of the Stock Exchanges on which the company’s shares are listed: BSE Limited National Stock Exchange of India Limited New York Stock Exchange Inc. (ADRs) NSE IFSC Limited (ADRs) |
| 3 |
Filing date of the statement referred in Regulation 10(b) of the SEBI (Share Based Employee Benefits) Regulations, 2014 with Stock Exchange: The Schemes were institutionalised under the erstwhile SEBI (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and appropriate details under Schedule V were filed. The Schemes complies with provisions of SEBI (Share Based Employee Benefits) Regulation, 2014. |
| 4 | Filing Number, if any : NA |
| 5 |
Title of the Scheme pursuant to which shares are issued, if any: Dr. Reddy’s Employees Stock Options Scheme, 2002 and Dr. Reddy’s Employees ADR Stock Options Scheme, 2007 |
| 6 | Kind of security to be listed: Equity Shares |
| 7 | Par value of the shares: Rs. 5/- |
| 8 | Date of issue of shares: October 28, 2021 (Date of allotment on exercise) |
| 9 | Number of shares issued: 1,114 equity shares |
| 10 | Share Certificate No., if applicable: NA |
| 11 | Distinctive number of the share, if applicable : 171476316 to 171477429 |
| 12 | ISIN Number of the shares if issued in Demat: INE089A01023 |
| 13 | Exercise price per share: 1,114 equity shares exercised at Rs. 5/- per share |
| 14 | Premium per share: Nil |
| 15 | Total Issued shares after this issue : 166,400,125 (*) |
| 16 | Total Issued share capital after this issue : Rs. 832,000,625/- |
| 17 | Details of any lock-in on the shares : NA |
| 18 | Date of expiry of lock-in: NA |
| 19 |
Whether shares identical in all respects to existing shares if not, when will they become identical?: Yes, the shares rank pari passu with the existing shares |
| 20 | Details of listing fees, if payable : NA |
(*) Total paid up capital after this issue: 166,399,925 i.e. Rs. 831,999,625 (difference of 200 due to forfeited shares of Rs. 5/- each in September 1988 due to non-payment of allotment money.)
Exhibit 99.5
 |
Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com |
October 29, 2021
To,
The Secretary
BSE Limited
National Stock Exchange of India Ltd.
New York Stock Exchange Inc.
NSE IFSC Limited
Dear Sir/ Madam,
Sub: Intimation
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in reference to our intimation dated October 7, 2021, please note that the Earnings Call for the quarter ended September 30, 2021, was held on October 29, 2021, at 5.30 pm IST and the audio recording of the call has been uploaded on our website.
The weblink to access it is:
https://www.drreddys.com/investors/presentations/earnings-call/?year=FY22
This is for your information and record.
Yours faithfully,
For Dr. Reddy's Laboratories Limited
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |